These agents are FDA-approved primarily for the management of type 2 diabetes mellitus and, for specific products (Wegovy, Saxenda, Zepbound), for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
Experts, however, are starting to gain some clues as to how common these apparent shifts in food preference and taste really are among users and what might be behind them
These habits support sustainable weight management and enhance the effectiveness of semaglutide and Mounjaro
The short answer: yes, you can use topical GHK-Cu alongside GLP-1 therapy without concern
The researchers note that about a quarter of those on the lowest dose of these medications gained weight
In higher doses, its known as the weight-loss injection Wegovy